WO2003011851A3 - Aromatic hydroxamic acid derivatives useful as hdac inhibitors - Google Patents

Aromatic hydroxamic acid derivatives useful as hdac inhibitors Download PDF

Info

Publication number
WO2003011851A3
WO2003011851A3 PCT/EP2002/006488 EP0206488W WO03011851A3 WO 2003011851 A3 WO2003011851 A3 WO 2003011851A3 EP 0206488 W EP0206488 W EP 0206488W WO 03011851 A3 WO03011851 A3 WO 03011851A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivatives
hydroxamic acid
hdac inhibitors
derivatives useful
aromatic hydroxamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/006488
Other languages
French (fr)
Other versions
WO2003011851A2 (en
Inventor
Ulrike Leser-Reiff
Tim Sattelkau
Gerd Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0210424-5A priority Critical patent/BR0210424A/en
Priority to HR20031019A priority patent/HRP20031019A2/en
Priority to NZ529874A priority patent/NZ529874A/en
Priority to DE60215652T priority patent/DE60215652T2/en
Priority to EP02791436A priority patent/EP1401824B1/en
Priority to IL15909702A priority patent/IL159097A0/en
Priority to AU2002355626A priority patent/AU2002355626B2/en
Priority to MXPA03011501A priority patent/MXPA03011501A/en
Priority to JP2003517043A priority patent/JP4195377B2/en
Priority to CA002449804A priority patent/CA2449804A1/en
Priority to YUP-982/03A priority patent/RS98203A/en
Priority to SK17-2004A priority patent/SK172004A3/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to HU0401233A priority patent/HUP0401233A3/en
Priority to HK04108497.7A priority patent/HK1065787B/en
Priority to KR1020037016358A priority patent/KR100910958B1/en
Publication of WO2003011851A2 publication Critical patent/WO2003011851A2/en
Publication of WO2003011851A3 publication Critical patent/WO2003011851A3/en
Priority to NO20035555A priority patent/NO20035555D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compounds of formula (I) wherein A, R1 and R2 have the meanings defined in the specification, process of manufacturing these compounds and medicaments with HDAC inhibitor activity containing such a compound.
PCT/EP2002/006488 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors Ceased WO2003011851A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
YUP-982/03A RS98203A (en) 2001-06-15 2002-06-13 Aromatic dicarboxylic acid derivatives
NZ529874A NZ529874A (en) 2001-06-15 2002-06-13 Aromatic dicarboxylic acid derivatives useful as HDAC inhibitors
DE60215652T DE60215652T2 (en) 2001-06-15 2002-06-13 AROMATIC HYDROXAMIC ACID DERIVATIVES SUITED AS HDAC INHIBITORS
EP02791436A EP1401824B1 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
IL15909702A IL159097A0 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
AU2002355626A AU2002355626B2 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as HDAC inhibitors
MXPA03011501A MXPA03011501A (en) 2001-06-15 2002-06-13 Aromatic dicarboxylic acid derivatives.
JP2003517043A JP4195377B2 (en) 2001-06-15 2002-06-13 Aromatic carboxylic acid derivatives
CA002449804A CA2449804A1 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
BR0210424-5A BR0210424A (en) 2001-06-15 2002-06-13 Aromatic Dicarboxylic Acid Derivatives
HR20031019A HRP20031019A2 (en) 2001-06-15 2002-06-13 Aromatic dicarboxylic acid derivatives
SK17-2004A SK172004A3 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as HDAC inhibitors
HU0401233A HUP0401233A3 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
HK04108497.7A HK1065787B (en) 2001-06-15 2002-06-13 Aromatic dicarboxylic acid derivatives
KR1020037016358A KR100910958B1 (en) 2001-06-15 2002-06-13 Aromatic Hydroxamic Acid Derivatives Useful as HADAC Inhibitors
NO20035555A NO20035555D0 (en) 2001-06-15 2003-12-12 Aromatic dicarboxylic acid derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01114496 2001-06-15
EP01114496.1 2001-06-15

Publications (2)

Publication Number Publication Date
WO2003011851A2 WO2003011851A2 (en) 2003-02-13
WO2003011851A3 true WO2003011851A3 (en) 2003-09-18

Family

ID=8177731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006488 Ceased WO2003011851A2 (en) 2001-06-15 2002-06-13 Aromatic hydroxamic acid derivatives useful as hdac inhibitors

Country Status (32)

Country Link
US (2) US6784173B2 (en)
EP (1) EP1401824B1 (en)
JP (1) JP4195377B2 (en)
KR (2) KR100910958B1 (en)
CN (1) CN1271066C (en)
AR (1) AR036055A1 (en)
AT (1) ATE343569T1 (en)
AU (1) AU2002355626B2 (en)
BG (1) BG108450A (en)
BR (1) BR0210424A (en)
CA (1) CA2449804A1 (en)
CO (1) CO5540280A2 (en)
CZ (1) CZ200425A3 (en)
DE (1) DE60215652T2 (en)
EC (1) ECSP034896A (en)
ES (1) ES2272800T3 (en)
GT (1) GT200200121A (en)
HR (1) HRP20031019A2 (en)
HU (1) HUP0401233A3 (en)
IL (1) IL159097A0 (en)
MA (1) MA27041A1 (en)
MX (1) MXPA03011501A (en)
NO (1) NO20035555D0 (en)
NZ (1) NZ529874A (en)
PA (1) PA8548001A1 (en)
PE (1) PE20030086A1 (en)
PL (1) PL366729A1 (en)
RS (1) RS98203A (en)
RU (1) RU2289580C2 (en)
SK (1) SK172004A3 (en)
WO (1) WO2003011851A2 (en)
ZA (1) ZA200309260B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
CA2476067C (en) 2002-03-13 2011-09-20 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
BR0308908A (en) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Compound, composition, use of a compound, and methods for inhibiting hdac in a cell for the treatment of an hdac-mediated condition, a proliferative condition, cancer, and psoriasis
TW200418825A (en) * 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
TW200424187A (en) * 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
US7935724B2 (en) * 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7217723B2 (en) 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
US20050203081A1 (en) * 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B
AR047894A1 (en) * 2004-02-25 2006-03-01 Wyeth Corp THIOPHEN DERIVATIVES AS INHIBITORS OF PROTEIN THYROSINE PHOSPHATASE 1B (PTPASA 1B); METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY PTPASA 1B
CN1980920A (en) * 2004-06-14 2007-06-13 霍夫曼-拉罗奇有限公司 Thiophene derivatives, their manufacture and use as pharmaceutical agents
JP2008501665A (en) * 2004-06-14 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
CN1964963A (en) * 2004-06-14 2007-05-16 霍夫曼-拉罗奇有限公司 Hydroxamates, their manufacture and use as pharmaceutical agents
KR100620488B1 (en) 2004-08-13 2006-09-08 연세대학교 산학협력단 Novel histone deacetylase inhibitors and preparation methods thereof
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
CN101163690A (en) * 2005-04-20 2008-04-16 默克公司 Benzothiophene Hydroxamic Acid Derivatives
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
AR057579A1 (en) * 2005-11-23 2007-12-05 Merck & Co Inc SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
EP2338878A3 (en) * 2005-12-15 2011-11-16 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP5247470B2 (en) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP5043120B2 (en) 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド Hydroxamates as inhibitors of histone deacetylase
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
CA2701115A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (en) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク Histone deacetylase inhibitor
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
PT2970139T (en) 2013-03-15 2018-08-01 Biomarin Pharm Inc Hdac inhibitors
EP2826769A1 (en) 2013-07-18 2015-01-21 Institut de Recherche pour le Développement ( IRD) Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof
KR101536050B1 (en) * 2013-07-30 2015-07-13 충북대학교 산학협력단 Novel Isatin-Based Hydroxamic Acids and Anti-Cancer Composition Comprising the Same As Active Ingredient
EP3062783B1 (en) 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
MX2016011833A (en) * 2014-03-12 2017-03-29 Chong Kun Dang Pharmaceutical Corp Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same.
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
WO2024123700A1 (en) * 2022-12-05 2024-06-13 The General Hospital Corporation Histone deacetylase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279836A (en) * 1978-05-12 1981-07-21 Asahi Kasei Kogyo Kabushiki Kaisha Hydroxamic acid derivative and method of preparing metoclopramide using same
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
EP0847992A1 (en) * 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
WO2001038322A1 (en) * 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3825554A (en) * 1969-06-13 1974-07-23 Atlantic Richfield Co Method for preparing cyclic nitrile carbonates
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279836A (en) * 1978-05-12 1981-07-21 Asahi Kasei Kogyo Kabushiki Kaisha Hydroxamic acid derivative and method of preparing metoclopramide using same
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
EP0847992A1 (en) * 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
WO2001038322A1 (en) * 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHAN, MOHAMMED NIYAZ: "The kinetics and mechanism of a highly efficient intramolecular nucleophilic reaction. The cyclization of ethyl N-[o-(N-hydroxycarbamoyl)benzoyl]carbamate to N-hydroxyphthalimide", J. CHEM. SOC., PERKIN TRANS. 2 (1988), (2), 213-19, XP001094387 *
KOBASHI, KYOICHI ET AL: "Effect of acyl residues of hydroxamic acids on urease inhibition", BIOCHIM. BIOPHYS. ACTA (1971), 227(2), 429-41, XP001094532 *
RANADIVE V B ET AL: "NUCLEOPHILIC REACTIONS OF N-HYDROXY-, METHOXY-,2,3-EPOXYPROPOXY-PHTHA LIMIDES", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI, IN, vol. 12, no. 33B, December 1994 (1994-12-01), pages 1175 - 1177, XP001087547, ISSN: 0019-5103 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US7399884B2 (en) 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors

Also Published As

Publication number Publication date
ZA200309260B (en) 2005-02-28
NO20035555D0 (en) 2003-12-12
RU2003137578A (en) 2005-05-20
AU2002355626B2 (en) 2008-09-25
CN1271066C (en) 2006-08-23
HUP0401233A3 (en) 2007-05-29
EP1401824A2 (en) 2004-03-31
RS98203A (en) 2007-02-05
DE60215652D1 (en) 2006-12-07
BG108450A (en) 2005-01-31
KR100910958B1 (en) 2009-08-05
IL159097A0 (en) 2004-05-12
HK1065787A1 (en) 2005-03-04
CA2449804A1 (en) 2003-02-13
CN1516697A (en) 2004-07-28
US6784173B2 (en) 2004-08-31
ES2272800T3 (en) 2007-05-01
KR20090059172A (en) 2009-06-10
KR20040018270A (en) 2004-03-02
ECSP034896A (en) 2004-01-28
CO5540280A2 (en) 2005-07-29
PL366729A1 (en) 2005-02-07
US20030013757A1 (en) 2003-01-16
NZ529874A (en) 2004-12-24
SK172004A3 (en) 2004-07-07
US20040214862A1 (en) 2004-10-28
MA27041A1 (en) 2004-12-20
HRP20031019A2 (en) 2005-08-31
AR036055A1 (en) 2004-08-04
HUP0401233A2 (en) 2004-10-28
EP1401824B1 (en) 2006-10-25
GT200200121A (en) 2003-06-19
ATE343569T1 (en) 2006-11-15
RU2289580C2 (en) 2006-12-20
JP2005502641A (en) 2005-01-27
PE20030086A1 (en) 2003-02-08
JP4195377B2 (en) 2008-12-10
BR0210424A (en) 2004-08-17
MXPA03011501A (en) 2004-03-09
WO2003011851A2 (en) 2003-02-13
DE60215652T2 (en) 2007-08-23
PA8548001A1 (en) 2003-01-24
CZ200425A3 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
MXPA03011501A (en) Aromatic dicarboxylic acid derivatives.
YU48803A (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
WO2004000820A3 (en) Certain aromatic monocycles as kinase modulators
CA2477839A1 (en) Nitrogen containing heterocyclic compounds and medicines containing the same
WO2004018451A8 (en) Pyridazinone-derivatives as pde4 inhibitors
WO2002100860A3 (en) Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as anti-bacterial agents
WO2004018457A8 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
MXPA04008797A (en) Inhibitors of histone deacetylase.
PL370982A1 (en) Carbonylamino-derivatives as novel inhibitors of histone deacetylase
PL371036A1 (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2003045878A8 (en) 2,w-diaminocarboxylic acid compounds
BR0317348A (en) Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
WO2005005389A3 (en) Malonamide derivatives
WO2002076918A8 (en) NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
WO2004052891A8 (en) Heterocyclic compounds, preparation method thereof and use of same as medicaments, such as anti-bacterial medicaments and beta-lactamase inhibitors
WO2001085680A3 (en) Sulfonyl aryl or heteroaryl hydroxamic acid compounds
HK1045501A1 (en) Hydroxamic acid derivatives as matrix metalloprotease inhibitors
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
MXPA04009476A (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors.
WO2003007954A3 (en) Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
HK1047276A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-982/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2003-501292

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003/09260

Country of ref document: ZA

Ref document number: 159097

Country of ref document: IL

Ref document number: 200309260

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 529874

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002791436

Country of ref document: EP

Ref document number: 2449804

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002355626

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20031019A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 03108279

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011501

Country of ref document: MX

Ref document number: 1981/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020037016358

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 10845002

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003517043

Country of ref document: JP

Ref document number: 028120108

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2004-25

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 172004

Country of ref document: SK

WWP Wipo information: published in national office

Ref document number: 2002791436

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2004-25

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 529874

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529874

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002791436

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097010546

Country of ref document: KR